Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuning Le

Showing results (61-70 of 179) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Garassino, et al.
JTO Clinical and Research Reports|November 25, 2021
Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With <i>EGFR</i> or <i>ALK</i> AlterationsWhitney E Lewis, Lingzhi Hong, Frank E Mott, et al.
Cancer Medicine|March 11, 2024
Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screeningSara Nofal, Jiangong Niu, Paul Resong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 25, 2022
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung AdenocarcinomaNatalie I Vokes, Emily Chambers, Tom Nguyen, et al.
Genes & Development|May 19, 2007
Effects of RAS on the genesis of embryonal rhabdomyosarcomaDavid M Langenau, Matthew D Keefe, Narie Y Storer, et al.
Eclinicalmedicine|March 4, 2025
Ensartinib for advanced or metastatic non-small-cell lung cancer with <i>MET</i> exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialYang Xia, Panwen Tian, Mo Zhou, et al.
NPJ Precision Oncology|October 1, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patientsLingzhi Hong, Sonia Patel, Leylah M Drusbosky, et al.
Genes & Development|April 17, 2024
Corrigendium: Effects of RAS on the genesis of embryonal rhabdomyosarcomaDavid M Langenau, Matthew D Keefe, Narie Y Storer, et al.
Cancer Treatment Communications|November 25, 2015
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practiceDeepa Rangachari, Paul A VanderLaan, Xiuning Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLCXiuning Le, Monique Nilsson, Jonathan Goldman, et al.
Pageof 18

Showing results (61-70 of 179) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Garassino, et al.
JTO Clinical and Research Reports|November 25, 2021
Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With <i>EGFR</i> or <i>ALK</i> AlterationsWhitney E Lewis, Lingzhi Hong, Frank E Mott, et al.
Cancer Medicine|March 11, 2024
Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screeningSara Nofal, Jiangong Niu, Paul Resong, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 25, 2022
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung AdenocarcinomaNatalie I Vokes, Emily Chambers, Tom Nguyen, et al.
Genes & Development|May 19, 2007
Effects of RAS on the genesis of embryonal rhabdomyosarcomaDavid M Langenau, Matthew D Keefe, Narie Y Storer, et al.
Eclinicalmedicine|March 4, 2025
Ensartinib for advanced or metastatic non-small-cell lung cancer with <i>MET</i> exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trialYang Xia, Panwen Tian, Mo Zhou, et al.
NPJ Precision Oncology|October 1, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patientsLingzhi Hong, Sonia Patel, Leylah M Drusbosky, et al.
Genes & Development|April 17, 2024
Corrigendium: Effects of RAS on the genesis of embryonal rhabdomyosarcomaDavid M Langenau, Matthew D Keefe, Narie Y Storer, et al.
Cancer Treatment Communications|November 25, 2015
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practiceDeepa Rangachari, Paul A VanderLaan, Xiuning Le, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLCXiuning Le, Monique Nilsson, Jonathan Goldman, et al.
Pageof 18